RT Journal Article
SR Electronic
T1 Symptoms of COVID-19 in a population-based cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.20.21254040
DO 10.1101/2021.03.20.21254040
A1 Khan, Sana M.
A1 Farland, Leslie V.
A1 Austhof, Erika
A1 Bell, Melanie L.
A1 Catalfamo, Collin J.
A1 Chen, Zhao
A1 Cordova-Marks, Felina
A1 Ernst, Kacey C.
A1 Garcia-Filion, Pamela
A1 Heslin, Kelly M.
A1 Hoskinson, Joshua
A1 Jehn, Megan L
A1 Joseph, Emily C.S.
A1 Kelley, Connor P.
A1 Klimentidis, Yann
A1 Carroll, Stephanie Russo
A1 Kohler, Lindsay N.
A1 Pogreba-Brown, Kristen
A1 Jacobs, Elizabeth T.
YR 2021
UL http://medrxiv.org/content/early/2021/03/22/2021.03.20.21254040.abstract
AB Accurate diagnosis of potential SARS-CoV-2 infections by symptoms is one strategy for continuing global surveillance, particularly in low-resource communities. We conducted a prospective, population-based cohort study, the Arizona CoVHORT, among Arizona residents to elucidate the symptom profile of laboratory-confirmed COVID-19 participants(16.2%) compared to laboratory-confirmed negative(22.4%) and untested general population participants(61.4%). Among the 1514 study participants, those who were COVID-19 positive were more likely to be Hispanic(33.5%) and more likely to report obesity > 30 kg/m2(34.7%) compared to COVID-19 negative participants(19.2%; 31.0%) and untested CoVHORT participants(13.8%; 23.8%). Of the 245 laboratory-confirmed COVID-19 cases, 15.0% reported having had no symptoms. Of those that did report symptoms, the most commonly-reported first symptoms were sore throat(19.0%), headache(15.5%), cough(12.7%), runny nose/cold-like symptoms(12.1%), and fatigue(12.0%). In adjusted logistic regression models, COVID-19 positive participants were more likely than negative participants to experience loss of taste and smell(OR:35.7; 95% CI 18.4-69.5); bone or nerve pain(OR:17.9; 95% CI 6.7-47.4), vomiting(OR:10.8; 95% CI 3.1-37.5), nausea(OR:10.5; 95% CI 5.5-19.9), and headache(OR:8.4; 95% CI 5.6-12.8). When comparing confirmed COVID-19 cases with confirmed negative or untested participants, the pattern of symptoms that discriminates SARS-CoV-2 infection from those arising from other potential circulating pathogens may differ from general reports of symptoms among cases alone.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/33643990/ Funding StatementThis study has been funded by a seed grant awarded by the BIO5 Institute at the University of Arizona. The sponsors have no role or authority over the design or implementation of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures are conducted in accordance with approval by the University of Arizona Institutional Review Board (#2003521636A002) under the aegis of the University of Arizona Human Subjects Protection Program.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not currently available for public use.